title: Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients.
abstract: The benefit of oral iron therapy (OIT) and factors predictive of OIT response are not established in hemodialysis (HD) patients with iron deficiency anemia (IDA). We examined the values of hepcidin-25, mean corpuscular volume (MCV), and ferritin as predictors of OIT response. Oral ferrous fumarate (50 mg/day, 8 weeks) was given to 51 HD patients with IDA (hemoglobin (Hb) < 12 g/dL, ferritin < 100 ng/mL) treated with an erythropoietin activator. Sixteen patients were responders (improvement of Hb (ΔHb) ≥ 2 g/dL) and 35 were non-responders (ΔHb < 2g/dL). Baseline Hb, MCV, serum hepcidin-25, ferritin, iron parameters, and C-reactive protein (CRP) before and ΔHb after OIT were compared between groups. Hepcidin-25, MCV, ferritin, and transferrin saturation were lower in the responders than in the non-responders. Hepcidin-25 positively correlated with ferritin. Hepcidin-25, MCV, and ferritin positively correlated with baseline Hb and negatively correlated with ΔHb. Despite normal CRP levels in all patients, CRP correlated positively with hepcidin-25 and ferritin. Stepwise multiple linear regression analysis and receiver operating characteristics curve analysis revealed that hepcidin-25, MCV, and ferritin could predict OIT response. We conclude that hepcidin-25, MCV, and ferritin could be useful markers of iron storage status and may help predict OIT response in HD patients.
authors.affiliation: Renal Division, Public Central Hospital of Matto Ishikawa, 3-8 Kuramitsu, Hakusan, Ishikawa 924-8588, Japan. kazuya@takasawa.org.
authors.forename: Kazuya
authors.initials: K
authors.lastname: Takasawa
authors.affiliation: Renal Division, Public Central Hospital of Matto Ishikawa, 3-8 Kuramitsu, Hakusan, Ishikawa 924-8588, Japan. takaeda@imcc-med.com.
authors.forename: Chikako
authors.initials: C
authors.lastname: Takaeda
authors.affiliation: Biomarker Society, 1-403 Kosugi, Nakahara, Kawasaki, Kanagawa 211-0063, Japan. dr.tanuki@maeda-irr.com.
authors.forename: Teiryo
authors.initials: T
authors.lastname: Maeda
authors.affiliation: Department of Pediatrics, Public Central Hospital of Matto Ishikawa, 3-8 Kuramitsu, Hakusan, Ishikawa 924-8588, Japan. nueda@mattohp.com.
authors.forename: Norishi
authors.initials: N
authors.lastname: Ueda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism; D019587:Dietary Supplements; D004909:Erythrocyte Indices / Q000502:physiology*; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood*; D005296:Ferrous Compounds / Q000008:administration & dosage; D006454:Hemoglobins / Q000378:metabolism; D064451:Hepcidins / Q000097:blood*; D006801:Humans; D019266:Iron, Dietary / Q000008:administration & dosage*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
chemical_list: D015415:Biomarkers; D005296:Ferrous Compounds; D006454:Hemoglobins; D064451:Hepcidins; D019266:Iron, Dietary; D004921:Erythropoietin; D002097:C-Reactive Protein; D005293:Ferritins; C031621:ferrous fumarate